Abstract
Testicular germ cell tumors (TGCTs) are unique to that of most other solid tumors because they are highly curable in the metastatic setting. While the use of cisplatin-based chemotherapy continues to drive cure in this patient population, important improvements in the delivery of therapy, creation of risk-adjusted treatment paradigms, and salvage-therapy options have further enhanced survival as well. The future holds promise for a more multidisciplinary approach to care, through advancements in biochemical markers and a better understanding of how surgical and radiotherapy approaches can integrate into our existing management strategies.
Keywords: Metastatic, testicular germ cell tumor (TGCTs), systemic therapies, risk stratification, solid tumors, chemotherapy.
Graphical Abstract
[2]
Huyghe E. Matsuda Tomohiro, Thonneau P. Increasing incidence of testicular cancer worldwide: A review. J Urol 2003; 170(1): 5-11.
[4]
MacKenzie AR. Chemotherapy of metastatic testis cancer: Results in 154 patients. Cancer 1966; 19: 1369-76.
[5]
Samuels ML, Lanzotti VJ, Holoye PY, et al. Combination chemotherapy in germinal cell tumors. Cancer Treat Rev 1976; 3: 185-204.
[6]
Einhorn LH. Treatment of testicular cancer: A new and improved model. J Clin Oncol 1990; 8(11): 1777-81.
[7]
Rosenberg B, Vancamp L, Krigas T. Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature 1965; 205: 698-9.
[8]
Higby DJ, Wallace HJ, Albert DJ, Holland JF. Diaminodichloro-platinum: A phase I study showing responses in testicular and other tumors. Cancer 1974; 33(5): 1219-5.
[9]
Einhorn LH, Donohue J. Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Intern Med 1977; 87(3): 293-8.
[10]
Mead GM. International germ cell consensus classification: A prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 1997; 15(2): 594-603.
[11]
Fitzharris BM, Kaye SB, Saverymuttu S, et al. VP16-213 as a single agent in advanced testicular tumors. Eur J Cancer Clin Oncol 1980; 16(9): 1193-7.
[12]
Williams SD, Birch R, Einhorn LH, Irwin L, Greco FA, Loehrer PJ. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 1987; 316(23): 1435-40.
[13]
Ko JJ, Bernard B, Tran B, et al. Conditional survival of patients with metastatic testicular germ cell tumors treated with first-line curative therapy. J Clin Oncol 2016; 34(7): 714-20.
[14]
Einhorn LH, Williams SD, Loehrer PJ, et al. Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors: A Southeastern Cancer Study Group Protocol. J Clin Oncol 1989; 7(3): 387-91.
[15]
Bajorin DF, Sarosdy MF, Pfister DG, et al. Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: A multiinstitutional study. J Clin Oncol 1993; 11(4): 598-606.
[16]
Loehrer PJ, Johnson D, Elson P, Einhorn LH, Trump D. Importance of bleomycin in favorable-prognosis disseminated germ cell tumors: An Eastern Cooperative Oncology Group trial. J Clin Oncol 1995; 13(2): 470-6.
[17]
Culine C, Theodore C, Terrier-Lacombe MJ, Droz JP. Are 3 cycles of bleomycin, etoposide and cisplatin or 4 cycles of etoposide and cisplatin equivalent optimal regimens for patients with good risk metastatic germ cell tumors of the testis? The need for a randomized trial. J Urol 1997; 157(3): 855-8.
[18]
Horwich A, Sleijfer DT, Fossa SD, et al. Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: A Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial. J Clin Oncol 1997; 15: 1844-52.
[19]
de Wit R, Stoter G, Kaye SB, et al. Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: A randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. J Clin Oncol 1997; 15(5): 1837-43.
[20]
Saxman SB, Finch D, Gonin R, Einhorn LH. Long-term follow-up of a phaseIII study of three versus four cycles of bleomycin, etoposide and cisplatin in favorable-prognosis germ-cell tumors: The Indiana University Experience. J Clin Oncol 1998; 16(2): 702-6.
[21]
de Wit R, Roberts JT, Wilkinson PM, et al. Equivalence of three of four cycles of bleomycin, etoposide, adn cisplatin chemotherapy and of a 3 or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council. J Clin Oncol 2001; 19: 1629-40.
[22]
O’Sullivan JM, Huddart RA, Norman AR, Nicholls J, Dearnaley DP, Horwich A. Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours. Ann Oncol 2003; 14(1): 91-6.
[23]
Travis LB, Fossa SD, Schonfeld SJ, et al. Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst 2005; 97(18): 1354-65.
[24]
Bahl G, Pathak RS, Sia M, et al. The use of chemotherapy instead of radiation therapy does not reduce the incidence of second cancers in survivors of early-stage seminoma: A population-based study from British Columbia. Int J Radiat Oncol Biol Phys 2017; 99(2): S209.
[25]
Warszawski N, Schmucking M. Relapses in early-stage testicular seminoma: Radiation therapy versus retroperitoneal lymphadenectomy. Scand J Urol Nephrol 1997; 31(4): 355-9.
[26]
Nichols CR, Williams SD, Loehrer PJ, et al. Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: A southeastern cancer study group and southwest oncology group protocol. J Clin Oncol 1991; 9(7): 1163-72.
[27]
Nichols CR, Catalano PJ, Crawford ED, et al. Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B study. J Clin Oncol 1998; 16: 1287-93.
[28]
Kaye SB, Mead GM, Fossa A, et al. Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: A randomized Medical Research Council/European Organization for Research and Treatment of Cancer. J Clin Oncol 1998; 16: 692-701.
[29]
Motzer RJ, Nichols CJ, Margolin KA, et al. Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. J Clin Oncol 2007; 25(3): 247-56.
[30]
Culine S, Kramar A, Théodore C, et al. Randomized trial comparing bleomycin/etoposide/cisplatin with alternating cisplatin/cyclophosphamide/doxorubicin and vinblastine/bleomycin regimens of chemotherapy for patients with intermediate- and poor-risk metastatic nonseminomatous germ cell tumors. J Clin Oncol 2008; 26(3): 421-7.
[31]
Daugaard G, Skoneczna I, Aass N, et al. A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem-cell support in males with poor-prognosis germ-cell cancer. An intergroup study of EORTC, GTCSG, and Grupo Germinal (EORTC 30974). Ann Oncol 2011; 22(5): 1054-61.
[32]
Fizazi K, Prow DM, Do K-A, et al. Alternating dose-dense chemotherapy in patients with high-volume disseminated nonseminomatous germ-cell tumors. Br J Cancer 2002; 86(10): 1555-60.
[33]
Fizazi K, Pagliaro L, Laplanche A, et al. Personalised chemotherapy based on tumor marker decline in poor prognosis germ-cell tumors (GETUG 13): A phase 3, multicentre, randomized trial. Lancet Oncol 2014; 15(13): 1442-50.
[34]
Gerl A, Clemm C, Schmeller N, et al. Late relapse of germ cell tumors after cisplatin-based chemotherapy. Ann Oncol 1997; 8(1): 41-7.
[35]
Sim HG, Lange PH, Lin DW. Role of post-chemotherapy surgery in germ cell tumors. Urol Clin North Am 2007; 34(2): 199-217.
[36]
Flechon A, Bompas E, Biron P, Droz J-P. Management of post-chemotherapy residual masses in advanced seminoma. J Urol 2002; 168(5): 1975-9.
[37]
De Santis M, Becherer A, Bokemeyer C, et al. 2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: An update of the prospective multicentric SEMPET trial. J Clin Oncol 2004; 22(6): 1034-9.
[38]
Oechsle K, Hartmann M, Brenner W, et al. [18F]Fluorode-oxyglucose positron emission tomography in nonseminomatous germ cell tumors after chemotherapy: The German multicenter positron emission tomography study group. J Clin Oncol 2008; 26(36): 5930-5.
[39]
Kesler KA, Kruter LE, Perkins SM, et al. Survival after resection for metastatic testicular nonseminomatous germ cell cancer to the lung or mediastinum. Ann Thorac Surg 2011; 91: 1085-93.
[40]
Feldman DR, Bosl GJ, Sheinfeld J, Motzer RJ. Medical treatment of advanced testicular cancer. JAMA 2008; 299(6): 672-84.
[41]
International Prognostic Factors Study Group, Lorch A, Beyer J, et
al. Prognostic factors in patients with metastatic germ cell tumor who experienced treatment failure with cisplatin based first-line chemotherapy. J Clin Oncol 2010; 28(33): 4906-11.
[42]
Segal R, Lukka H, Klotz LH, et al. Cancer care ontario practice guidelines initiative genitourinary cancer disease site group surveillance programs for early stage nonseminomatous testicular cancer: A practice guideline. Can J Urol 2001; 8(1): 1184-92.
[43]
Loehrer PJ, Lauer R, Roth BJ, Williams SD, Kalasinski LA, Einhorn LH. Salvage therapy in recurrent germ cell cancer: Ifosfamide and cisplatin plus either vinblastine or etoposide. Ann Intern Med 1988; 109(7): 540-6.
[44]
McCaffrey JA, Mazumdar M, Bajorin DF, Bosl GJ, Vlamis V, Motzer RJ. Ifosfamide- and cisplatin-containing chemotherapy as first-line salvage therapy in germ cell tumors: Response and survival. J Clin Oncol 1997; 15(7): 2559-63.
[45]
Loehrer PJ, Gonin R, Nichols CR, et al. Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor. J Clin Oncol 1998; 16(7): 2500-4.
[46]
Kondagunta GV, Bacik J, Donadio A, et al. Combination of paclitaxel, ifosfamide and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors. J Clin Oncol 2005; 23(27): 6549-55.
[47]
Mead GM, Cullen MH, Huddart R, et al. A phase II trial of TIP (paclitaxel, ifosfamide and cisplatin) given as second-line (post-BEP) salvage chemotherapy for patients with metastatic germ cell cancer: A medical research council trial. Br J Cancer 2005; 93: 178-84.
[48]
Nichols CR, Guido T, Williams SD. Dose-intensive chemotherapy in refractory germ cell cancer-A phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation. J Clin Oncol 1989; 7: 932-9.
[49]
Beyer J, Schwella N, Zingsem J, et al. Hematopoietic rescue after high-dose chemotherapy using autologous peripheral-blood progenitor cells or bone marrow: A randomized comparison. J Clin Oncol 1995; 13(6): 1328-35.
[50]
Einhorn LH, Williams SD, Chamness A, Brames MJ, Perkins SM, Abonour R. High-Dose Chemotherapy and stem-cell rescue for metastatic germ-cell tumors. N Engl J Med 2007; 357(4): 340-8.
[51]
Le Cornet C, Lortet-Tieulent J, Forman D, et al. Testicular cancer incidence to rise by 25% by 2025 in Europe? Model-based predictionsin 40 countries using population-based registry data. Eur J Cancer 2014; 50(4): 831-9.
[52]
Di Pietro A, Vries EG, Gietema JA, Spierings DC, de Jong S. Testicular germ cell tumours: The paradigm of chemo-sensitive solid tumours. Int J Biochem Cell Biol 2005; 37: 2437-56.
[53]
Welsh C, Day R, McGurk C, Masters JR, Wood RD, Köberle B. Reduced levels of XPA, ERCC1 and XPF DNA repair proteins in testis tumor cell lines. Int J Cancer 2004; 110: 352-61.
[54]
Peng HQ, Hogg D, Malkin D, et al. Mutations of the p53 gene do not occur in testis cancer. Cancer Res 1993; 53: 3574-8.
[55]
Chen X, Ko LJ, Jayaraman L, Prives C. p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells. Genes Dev 1996; 10: 2438-51.
[56]
Facchini G, Rossetti S, Cavaliere C, et al. Exploring the molecular aspects associated with testicular germ cell tumors: A review. Oncotarget 2018; 9(1): 1365-79.
[57]
Fung MK, Cheung HW, Ling MT, et al. Role of MEK/ERK pathway in the MAD2-mediated cisplatin sensitivity in testicular germ cell tumour cells. Br J Cancer 2006; 95: 475-84.
[58]
De Bono J. OUdard S, Ozguroglu M, et al Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial. Lancet 2010; 376(9747): 1147-54.
[59]
Oechsle K, Honecker F, Cheng T, et al. Preclinical and clinical activity of sunitnib in patients with cisplatin-refractory or multiply relaspsed germ cell tumors: A Canadian Urologic Oncology Group/German Testicular Cancer Study Group cooperative study. Ann Oncol 2011; 22(12): 2654-60.
[60]
Giannatempo P, Nicolai N, Fare E, et al. Activity of pazopanib in
chemo-resistant patients with germ cell tumors (GCT): First results
of the open-label, single-group, phase II PAZOTEST-01 trial. J
Clin Oncol 2014. 32(suppl 4): abstr367.
[61]
Skoneczna IA, Natorska U, Tacikowska M, et al. Sorafenib
monotherapy in patients with inoperable/recurrent germ cell tumors
(GCT) refractory to chemotherapy: Phase II study. J Clin Oncol 2014. 32(suppl 4): abstr367.
[62]
Einhorn LH, Brames MJ, Heinrich MC, et al. Phase II study of imatinib mesylate in chemotherapy refractory germ cell tumors expressing KIT. Am J Clin Oncol 2006; 29(1): 12-3.
[63]
Oechsle K, Bokemeyer C, Honecker F. Lenalidomide in patients with cisplatin-refractory and multiply relapsed germ cell tumors. J Cancer Res Clin Oncol 2010; 136(1): 165-7.
[64]
Rick O, Braun T, Seigert W, et al. Activity of thalidomide in patients with platinum-refractory germ-cell tumours. Eur J Cancer 2006; 42(12): 1775-9.
[65]
Zschabitz S, Lasitschka F, Jager D, et al. Activity of immune check-point inhibition in platinum refractory germ cell tumors. Ann Oncol 2016; 27(7): 1356-60.
[66]
Robert C, Ribas A, Hamid O, et al. Three-year overall survival for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. J Clin Oncol 2019; 30(4): 582-8.
[67]
Adra N, Einhorn LH, Althouse SK, et al. Phase II trial of pembrolizumab in patients with platinum refracotry germ-cell tumors: A Hoosier Cancer Research Network Study GU14-206. Ann Oncol 2018; 29(1): 209-14.
[68]
Fankhauser CD, Curioni-Fontecedro A, Allmann V, et al. Frequent PD-L1 expression in testicular germ cell tumors. Br J Cancer 2015; 113(3): 411-3.
Call for Papers in Thematic Issues
31 December, 2025
Advancements in Lipid Nanoparticle Delivery Systems for mRNA Therapeutics
The thematic issue "Advancements in Lipid Nanoparticle Delivery Systems for mRNA Therapeutics" aims to explore cutting-edge developments and innovative strategies in the field of lipid nanoparticle (LNP) technology, particularly focusing on its application in mRNA delivery. This topic has gained unprecedented attention and urgency in the wake of the COVID-19 ...read more
31 December, 2025
Current Progress in Protein Degradation and Cancer Therapy
Targeted Protein Degradation is gaining momentum in cancer therapy; it facilitates targeting undruggable proteins, overcomes cancer resistance, and avoids undesirable side effects. Thus small molecule degraders have emerged as novel therapeutic strategies. Targeted protein degradation (TPD), the process of eliminating a protein of interest holds a great promise for the ...read more
Related Journals
Anti-Cancer Agents in Medicinal Chemistry
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Current Bioactive Compounds
Current Cancer Drug Targets
Combinatorial Chemistry & High Throughput Screening
Current Diabetes Reviews
Current Drug Safety
Current Drug Targets
Current Drug Therapy
Current Drug Delivery
Related Books
Anthocyanins: Pharmacology and Nutraceutical Importance
The Roles and Responsibilities of Clinical Pharmacists in Hospital Settings
Bioactive Compounds from Medicinal Plants for Cancer Therapy and Chemoprevention
Drug Addiction Mechanisms in the Brain
Software and Programming Tools in Pharmaceutical Research
Objective Pharmaceutics: A Comprehensive Compilation of Questions and Answers for Pharmaceutics Exam Prep
Medicinal Chemistry of Drugs Affecting Cardiovascular and Endocrine Systems
Frontiers in Clinical Drug Research - Anti-Cancer Agents
The Management of Metastatic Triple-Negative Breast Cancer: An Integrated and Expeditionary Approach
Advanced Pharmacy
Article Metrics
86
3
1